Compare NPFD & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPFD | PRME |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.8M | 666.1M |
| IPO Year | N/A | 2022 |
| Metric | NPFD | PRME |
|---|---|---|
| Price | $19.04 | $3.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.42 |
| AVG Volume (30 Days) | 64.7K | ★ 3.8M |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 6.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,977,000.00 |
| Revenue This Year | N/A | $111.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 647.13 |
| 52 Week Low | $14.50 | $1.11 |
| 52 Week High | $18.07 | $6.94 |
| Indicator | NPFD | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 39.71 |
| Support Level | $19.04 | $3.33 |
| Resistance Level | $19.15 | $4.12 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 5.45 | 13.08 |
Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.